Prosecution Insights
Last updated: November 05, 2026
Application No. 17/769,795

INSECTICIDAL MIXTURES OF BIFENTHRIN AND CHLORANTRANILIPROLE

Final Rejection §103§112
Filed
Apr 18, 2022
Priority
Oct 18, 2019 — provisional 62/923,163 +2 more
Examiner
WRIGHT, SARAH C
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Fmc Agro Singapore Pte. Ltd.
OA Round
2 (Final)
42%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allowance Rate
241 granted / 574 resolved
-18.0% vs TC avg
Strong +46% interview lift
Without
With
+45.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
48 currently pending
Career history
630
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
56.0%
+16.0% vs TC avg
§102
9.6%
-30.4% vs TC avg
§112
16.5%
-23.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 574 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1, 3-4, 6-9, and 11-20 are pending. Claims 2, 5, and 10 are canceled. Claims 1, 3-4, 6 and 11 are amended. Claims 19-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no linking or generic claim. Claims 1, 3-4, 6, 11 and 16-18, previously examined on their merits in light of the species of tris-(2-ethylhexyl)phosphate for the Phosphate Ester of Formula I and suspension concentrate for the formulation type, are hereby examined as to all species. In light of Applicant’s assertion in the Response of May 18, 2026 that the claims now define the invention at the point of criticality by expressly limiting bifenthrin to 15-25 wt% in combination with the specified ratio of bifenthrin:chlorantraniliprole of 3:1 to 4.5:1 and formulation of suspension concentrate, the suspension concentrate formulation type is found to be allowable. Therefore, claims 1, 3-4, 6, 8-9, 11-15 and 16-18 are found to be free of the prior art. Claims 1, 3-4, 6, 8-9, 11-15 and 16-18 are examined herein as to all species. Previous Rejections Rejections and/or objections not reiterated from previous office actions are hereby withdrawn as are those rejections and/or objections expressly stated to be withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Objections/Rejections Withdrawn Claim Objection In light of the cancelation of claim 10 the objection to claim 10 is withdrawn as moot. Claim Rejections - 35 USC § 103 In light of the amendments to the claims and Applicants’ arguments the rejection of claims 1-6, 10-11 and 16-18 under 35 U.S.C. 103 as being unpatentable over CN 107668063 (2/9/2018)(“CN”) in view of Benfatti et al. US 2016/0050930 (2/25/2016) is withdrawn. Double Patenting In light of the amendments to the claims and Applicants’ arguments the rejection of claims 1-6, 10-11 and 16-18 are directed to an invention not patentably distinct from claims 12-15 and 18 of commonly assigned U.S. Patent No. 11559057 in view of Benfatti et al. US 2016/0050930 (2/25/2016) is withdrawn. In light of the amendments to the claims and Applicants’ arguments the rejection of claims 1-6, 10-11 and 16-18 as being unpatentable over claims 1, 6-9 and 11 of commonly assigned U.S. Patent No. 12262711 in view of Benfatti et al. US 2016/0050930 (2/25/2016) is withdrawn. In light of the amendments to the claims and Applicants’ arguments the provisional rejection of claims 1-6, 10-11 and 16-18 are provisionally rejected as being unpatentable over claims 1-6, 10-11 and 16-18 of commonly assigned U.S. Patent Appn. No. 19/079958 in view of Benfatti et al. US 2016/0050930 (2/25/2016) is withdrawn. New Rejections Claim Rejections - 35 USC §112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 6 and 12-15 are rejected under 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the applicant regards as the invention. Claim 6 is rejected for the recitation of “The insecticidal concentrate composition of claim 5”. Claim 5 is canceled so claim 6 depends from a canceled claim. For purposes of this office action claim 6 will be interpreted as if depending from claim 1. Claim 12 recites an improper Markush group “wherein each of the bifenthrin and the chlorantraniliprole concentration is.” See MPEP 2173.05(h). The group is listed using the alternative “or” and it is unclear whether the group is open ended or closed. This ambiguity has rendered the claim indefinite. A Markush grouping is a closed group of alternatives, i.e., the selection is made from a group "consisting of" (rather than "comprising" or "including") the alternative members. Abbott Labs., 334 F.3d at 1280, 67 USPQ2d at 1196. If a Markush grouping requires a material selected from an open list of alternatives (e.g., selected from the group "comprising" or "consisting essentially of" the recited alternatives), the claim should generally be rejected under 35 U.S.C. 112(b) as indefinite because it is unclear what other alternatives are intended to be encompassed by the claim. Claims 13-15 are rejected as depending from the rejected claim 12. Claim Rejections - 35 USC §112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 7-9, 11-12 are rejected under 35 U.S.C. 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 7 is rejected as being indefinite for failing to further limit in the recitation of “wherein the composition comprises (i) from 20 wt% to 35 wt% bifenthrin” wherein claim 7 depends from claim 1. Claim 1 recites an amount of bifenthrin of from 15 wt% to 25 wt% and the recitation of (i) from 20 wt% to 35 wt% bifenthrin broadens the scope of claim 1 as a dependent claim and therefore fails to further limit claim 1. Additionally, claim 7 is rejected as being indefinite for failing to further limit in the recitation of “from 10 wt% to 60 wt% of a carrier component” wherein claim 7 depends from claim 1. Claim 1 recites an amount of carrier component of from 20 wt% to 70 wt% and the recitation of “from 10 wt% to 60 wt% of a carrier component” broadens the scope of claim 1 as a dependent claim and therefore fails to further limit claim 1. This is a failure to further limit the claim from which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 8 is rejected as being indefinite for failing to further limit in the recitation of “wherein the composition comprises (i) from 15 wt% to 35 wt% bifenthrin” wherein claim 8 depends from claim 1. Claim 1 recites an amount of bifenthrin of from 15 wt% to 25 wt% and the recitation of (i) from 20 wt% to 35 wt% bifenthrin broadens the scope of claim 1 as a dependent claim and therefore fails to further limit claim 1. Additionally, claim 8 is rejected as being indefinite for failing to further limit in the recitation of “from 10 wt% to 60 wt% of a carrier component” wherein claim 8 depends from claim 1. Claim 1 recites an amount of carrier component of from 20 wt% to 70 wt% and the recitation of “from 10 wt% to 60 wt% of a carrier component” broadens the scope of claim 8 as a dependent claim and therefore fails to further limit claim 1. This is a failure to further limit the claim from which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 9 is rejected as being indefinite for failing to further limit in the recitation of “wherein the composition comprises (i) from 20 wt% to 35 wt% bifenthrin” wherein claim 9 depends from claim 1. Claim 1 recites an amount of bifenthrin of from 15 wt% to 25 wt% and the recitation of (i) from 20 wt% to 35 wt% bifenthrin broadens the scope of claim 1 as a dependent claim and therefore fails to further limit claim 1. Additionally, claim 9 is rejected as being indefinite for failing to further limit in the recitation of “from 10 wt% to 60 wt% of a carrier component” wherein claim 9 depends from claim 1. Claim 1 recites an amount of carrier component of from 20 wt% to 70 wt% and the recitation of “from 10 wt% to 60 wt% of a carrier component” broadens the scope of claim 1 as a dependent claim and therefore fails to further limit claim 1. This is a failure to further limit the claim from which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 11 is rejected as being indefinite for failing to further limit in the recitation of “from 0.1 wt% to 12 wt% of a rheology modifier component” wherein claim 11 depends from claim 1. Claim 1 recites an amount of rheology modifier component of from 0.05 wt% to 5 wt% and the recitation of “from 0.1 wt% to 12 wt% of a rheology modifier component” broadens the scope of claim 1 as a dependent claim and therefore fails to further limit claim 1. This is a failure to further limit the claim from which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 12 is rejected as being indefinite for failing to further limit in the recitation of “wherein each of the bifenthrin and the chlorantraniliprole concentration is less than 5 wt%, from 0.005 wt% to 4 wt%, from 0.01 to 1 wt%, from 0.01 wt% to 0.1 wt%, or from 0.01 to 0.05 wt%” wherein claim 12 depends from claim 1. Claim 1 recites a bifenthrin concentration of from 15 wt% to 25 wt% and a chlorantraniliprole concentration from 5 wt% to 9 wt%. The recitation of “wherein each of the bifenthrin and the chlorantraniliprole concentration is less than 5 wt%, from 0.005 wt% to 4 wt%, from 0.01 to 1 wt%, from 0.01 wt% to 0.1 wt%, or from 0.01 to 0.05 wt%” broadens the scope of claim 1 as a dependent claim and therefore fails to further limit claim 1. This is a failure to further limit the claim from which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Response to Arguments Applicants comments of August 31, 2026 have been considered carefully and have been found to be persuasive in light of the amendments to the claims. Applicants note the amendments to the claims and where support for the amendments can be found. Applicants argue that Chen no longer teaches or overlaps the amended claims. Applicants assert that Chen does not disclose or suggest a suspension concentrate comprising bifenthirin in the claims 15-25 wt% range, let alone with a bifenthrin-dominant ratio. Chen teaches a low-concentration bifenthrin formulation and does not disclose or suggest a suspension concentrate in which bifenthrin is present at or above 15 wt%. Applicants expressly assert that the claims now define the invention at the point of criticality by expressly limiting bifenthrin to 15-25 wt% in combination with the specified ratio and formulation. Examples 3 and 4 show the stability of the claimed formulations wherein the amount of bifenthrin is higher than 15 wt%. With respect to the nonstatutory double patenting rejections Applicants note the assertion of criticality and note that the cited claims in the double patenting rejections do not recite the required 15-25 wt% bifenthrin in a suspension concentrate. Applicants point to Exhibit 1 which summarizes the bifenthrin and chlorantraniliprole concentrations and formulation types that are explicitly disclosed in Chen Examples E1-E15. It shows that none of the Chen examples exemplifies a suspension concentrate containing bifenthin at or above 15 wt%. Applicants note that no suspension concentrate in Chen contains bifenthrinin in excess of chlorantraniliprole. Applicants’ obviousness arguments have been carefully considered and are found to be persuasive in light of the amendments to the claims and the assertion of criticality with respect to the content of these amendments. The obviousness rejections are withdrawn above. Please note the new indefiniteness rejections applied to the claims above. Conclusion Claims 1, 3-4 and 16-18 are allowed. Claims 6-9 and 11-15 are rejected. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH CHICKOS whose telephone number is (571)270-3884. The examiner can normally be reached on M-F 9-6. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Blanchard can be reached on 571-272-0827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SARAH CHICKOS/ Examiner, Art Unit 1619 /DAVID J BLANCHARD/Supervisory Patent Examiner, Art Unit 1619
Read full office action

Prosecution Timeline

Apr 18, 2022
Application Filed
Nov 18, 2025
Non-Final Rejection mailed — §103, §112
May 18, 2026
Response Filed
Oct 05, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766080
PERSONAL CARE COMPOSITION PRESERVATIVES LEVEL OPTIMIZATION
3y 11m to grant Granted Oct 20, 2026
Patent 12751911
LOW VISCOSITY NONAQUEOUS METAL OXIDE PARTICLE DISPERSIONS AND PROCESSES FOR PREPARING THE SAME
2y 11m to grant Granted Oct 06, 2026
Patent 12740931
COSMETIC OR DERMATOLOGICAL COMPOSITION ACTING IN PARTICULAR ON THE EFFECTS OF BLUE LIGHT ON SKIN AND ITS APPENDAGES, AND ASSOCIATED USES
4y 3m to grant Granted Sep 22, 2026
Patent 12653779
COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA
2y 9m to grant Granted Jun 16, 2026
Patent 12629327
KERATIN-BASED HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS
2y 9m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
42%
Grant Probability
88%
With Interview (+45.7%)
3y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 574 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month